Gene set variation analysis was then utilized to develop a gene signature (“METTL3 inhibitor response signature”) based on the subset of the consensus up-regulated gene set that was involved in nervous system development (GO: 0007399) (n = 73 genes), and the prognostic value of this gene signature was evaluated in two independent neuroblastoma patient cohorts. Here, METTL3 is linked to neuroblastoma.